Mobile Shelving
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Molecular Diagnostics Cancer Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Pharmacogenomic Diagnosis 1.2.3 Liquid Biopsy 1.2.4 Other 1.3 Market by Application 1.3.1 Global Molecular Diagnostics Cancer Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Respiratory Cancer 1.3.3 Cancer of Digestive System 1.3.4 Cancer of Urinary System 1.3.5 Cancer of Circulatory System 1.3.6 Motor System Cancer 1.3.7 Reproductive System Cancer 1.3.8 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Molecular Diagnostics Cancer Market Perspective (2017-2028) 2.2 Molecular Diagnostics Cancer Growth Trends by Region 2.2.1 Molecular Diagnostics Cancer Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Molecular Diagnostics Cancer Historic Market Size by Region (2017-2022) 2.2.3 Molecular Diagnostics Cancer Forecasted Market Size by Region (2023-2028) 2.3 Molecular Diagnostics Cancer Market Dynamics 2.3.1 Molecular Diagnostics Cancer Industry Trends 2.3.2 Molecular Diagnostics Cancer Market Drivers 2.3.3 Molecular Diagnostics Cancer Market Challenges 2.3.4 Molecular Diagnostics Cancer Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Molecular Diagnostics Cancer Players by Revenue 3.1.1 Global Top Molecular Diagnostics Cancer Players by Revenue (2017-2022) 3.1.2 Global Molecular Diagnostics Cancer Revenue Market Share by Players (2017-2022) 3.2 Global Molecular Diagnostics Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Molecular Diagnostics Cancer Revenue 3.4 Global Molecular Diagnostics Cancer Market Concentration Ratio 3.4.1 Global Molecular Diagnostics Cancer Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Molecular Diagnostics Cancer Revenue in 2021 3.5 Molecular Diagnostics Cancer Key Players Head office and Area Served 3.6 Key Players Molecular Diagnostics Cancer Product Solution and Service 3.7 Date of Enter into Molecular Diagnostics Cancer Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Molecular Diagnostics Cancer Breakdown Data by Type 4.1 Global Molecular Diagnostics Cancer Historic Market Size by Type (2017-2022) 4.2 Global Molecular Diagnostics Cancer Forecasted Market Size by Type (2023-2028) 5 Molecular Diagnostics Cancer Breakdown Data by Application 5.1 Global Molecular Diagnostics Cancer Historic Market Size by Application (2017-2022) 5.2 Global Molecular Diagnostics Cancer Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Molecular Diagnostics Cancer Market Size (2017-2028) 6.2 North America Molecular Diagnostics Cancer Market Size by Country (2017-2022) 6.3 North America Molecular Diagnostics Cancer Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Molecular Diagnostics Cancer Market Size (2017-2028) 7.2 Europe Molecular Diagnostics Cancer Market Size by Country (2017-2022) 7.3 Europe Molecular Diagnostics Cancer Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Molecular Diagnostics Cancer Market Size (2017-2028) 8.2 Asia-Pacific Molecular Diagnostics Cancer Market Size by Country (2017-2022) 8.3 Asia-Pacific Molecular Diagnostics Cancer Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Molecular Diagnostics Cancer Market Size (2017-2028) 9.2 Latin America Molecular Diagnostics Cancer Market Size by Country (2017-2022) 9.3 Latin America Molecular Diagnostics Cancer Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Molecular Diagnostics Cancer Market Size (2017-2028) 10.2 Middle East & Africa Molecular Diagnostics Cancer Market Size by Country (2017-2022) 10.3 Middle East & Africa Molecular Diagnostics Cancer Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Roche 11.1.1 Roche Company Detail 11.1.2 Roche Business Overview 11.1.3 Roche Molecular Diagnostics Cancer Introduction 11.1.4 Roche Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.1.5 Roche Recent Development 11.2 Danaher 11.2.1 Danaher Company Detail 11.2.2 Danaher Business Overview 11.2.3 Danaher Molecular Diagnostics Cancer Introduction 11.2.4 Danaher Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.2.5 Danaher Recent Development 11.3 Siemens 11.3.1 Siemens Company Detail 11.3.2 Siemens Business Overview 11.3.3 Siemens Molecular Diagnostics Cancer Introduction 11.3.4 Siemens Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.3.5 Siemens Recent Development 11.4 Abbott Laboratories 11.4.1 Abbott Laboratories Company Detail 11.4.2 Abbott Laboratories Business Overview 11.4.3 Abbott Laboratories Molecular Diagnostics Cancer Introduction 11.4.4 Abbott Laboratories Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.4.5 Abbott Laboratories Recent Development 11.5 ICON Plc 11.5.1 ICON Plc Company Detail 11.5.2 ICON Plc Business Overview 11.5.3 ICON Plc Molecular Diagnostics Cancer Introduction 11.5.4 ICON Plc Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.5.5 ICON Plc Recent Development 11.6 AstraZeneca 11.6.1 AstraZeneca Company Detail 11.6.2 AstraZeneca Business Overview 11.6.3 AstraZeneca Molecular Diagnostics Cancer Introduction 11.6.4 AstraZeneca Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.6.5 AstraZeneca Recent Development 11.7 MDxHealth 11.7.1 MDxHealth Company Detail 11.7.2 MDxHealth Business Overview 11.7.3 MDxHealth Molecular Diagnostics Cancer Introduction 11.7.4 MDxHealth Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.7.5 MDxHealth Recent Development 11.8 Invitae 11.8.1 Invitae Company Detail 11.8.2 Invitae Business Overview 11.8.3 Invitae Molecular Diagnostics Cancer Introduction 11.8.4 Invitae Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.8.5 Invitae Recent Development 11.9 PlexBio 11.9.1 PlexBio Company Detail 11.9.2 PlexBio Business Overview 11.9.3 PlexBio Molecular Diagnostics Cancer Introduction 11.9.4 PlexBio Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.9.5 PlexBio Recent Development 11.10 Thermo Fisher Scientific 11.10.1 Thermo Fisher Scientific Company Detail 11.10.2 Thermo Fisher Scientific Business Overview 11.10.3 Thermo Fisher Scientific Molecular Diagnostics Cancer Introduction 11.10.4 Thermo Fisher Scientific Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.10.5 Thermo Fisher Scientific Recent Development 11.11 Guardant Health 11.11.1 Guardant Health Company Detail 11.11.2 Guardant Health Business Overview 11.11.3 Guardant Health Molecular Diagnostics Cancer Introduction 11.11.4 Guardant Health Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.11.5 Guardant Health Recent Development 11.12 Biocartis 11.12.1 Biocartis Company Detail 11.12.2 Biocartis Business Overview 11.12.3 Biocartis Molecular Diagnostics Cancer Introduction 11.12.4 Biocartis Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.12.5 Biocartis Recent Development 11.13 Bio-Techne 11.13.1 Bio-Techne Company Detail 11.13.2 Bio-Techne Business Overview 11.13.3 Bio-Techne Molecular Diagnostics Cancer Introduction 11.13.4 Bio-Techne Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.13.5 Bio-Techne Recent Development 11.14 Merck 11.14.1 Merck Company Detail 11.14.2 Merck Business Overview 11.14.3 Merck Molecular Diagnostics Cancer Introduction 11.14.4 Merck Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.14.5 Merck Recent Development 11.15 Foundation Medicine 11.15.1 Foundation Medicine Company Detail 11.15.2 Foundation Medicine Business Overview 11.15.3 Foundation Medicine Molecular Diagnostics Cancer Introduction 11.15.4 Foundation Medicine Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.15.5 Foundation Medicine Recent Development 11.16 10X Genomics 11.16.1 10X Genomics Company Detail 11.16.2 10X Genomics Business Overview 11.16.3 10X Genomics Molecular Diagnostics Cancer Introduction 11.16.4 10X Genomics Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.16.5 10X Genomics Recent Development 11.17 Biodesix 11.17.1 Biodesix Company Detail 11.17.2 Biodesix Business Overview 11.17.3 Biodesix Molecular Diagnostics Cancer Introduction 11.17.4 Biodesix Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.17.5 Biodesix Recent Development 11.18 CytoTrack 11.18.1 CytoTrack Company Detail 11.18.2 CytoTrack Business Overview 11.18.3 CytoTrack Molecular Diagnostics Cancer Introduction 11.18.4 CytoTrack Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.18.5 CytoTrack Recent Development 11.19 GenomOncology 11.19.1 GenomOncology Company Detail 11.19.2 GenomOncology Business Overview 11.19.3 GenomOncology Molecular Diagnostics Cancer Introduction 11.19.4 GenomOncology Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.19.5 GenomOncology Recent Development 11.20 Luminex 11.20.1 Luminex Company Detail 11.20.2 Luminex Business Overview 11.20.3 Luminex Molecular Diagnostics Cancer Introduction 11.20.4 Luminex Revenue in Molecular Diagnostics Cancer Business (2017-2022) 11.20.5 Luminex Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
List of Tables Table 1. Global Molecular Diagnostics Cancer Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Pharmacogenomic Diagnosis Table 3. Key Players of Liquid Biopsy Table 4. Key Players of Other Table 5. Global Molecular Diagnostics Cancer Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 6. Global Molecular Diagnostics Cancer Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Molecular Diagnostics Cancer Market Size by Region (2017-2022) & (US$ Million) Table 8. Global Molecular Diagnostics Cancer Market Share by Region (2017-2022) Table 9. Global Molecular Diagnostics Cancer Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 10. Global Molecular Diagnostics Cancer Market Share by Region (2023-2028) Table 11. Molecular Diagnostics Cancer Market Trends Table 12. Molecular Diagnostics Cancer Market Drivers Table 13. Molecular Diagnostics Cancer Market Challenges Table 14. Molecular Diagnostics Cancer Market Restraints Table 15. Global Molecular Diagnostics Cancer Revenue by Players (2017-2022) & (US$ Million) Table 16. Global Molecular Diagnostics Cancer Market Share by Players (2017-2022) Table 17. Global Top Molecular Diagnostics Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Diagnostics Cancer as of 2021) Table 18. Ranking of Global Top Molecular Diagnostics Cancer Companies by Revenue (US$ Million) in 2021 Table 19. Global 5 Largest Players Market Share by Molecular Diagnostics Cancer Revenue (CR5 and HHI) & (2017-2022) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Molecular Diagnostics Cancer Product Solution and Service Table 22. Date of Enter into Molecular Diagnostics Cancer Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Molecular Diagnostics Cancer Market Size by Type (2017-2022) & (US$ Million) Table 25. Global Molecular Diagnostics Cancer Revenue Market Share by Type (2017-2022) Table 26. Global Molecular Diagnostics Cancer Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 27. Global Molecular Diagnostics Cancer Revenue Market Share by Type (2023-2028) Table 28. Global Molecular Diagnostics Cancer Market Size by Application (2017-2022) & (US$ Million) Table 29. Global Molecular Diagnostics Cancer Revenue Market Share by Application (2017-2022) Table 30. Global Molecular Diagnostics Cancer Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 31. Global Molecular Diagnostics Cancer Revenue Market Share by Application (2023-2028) Table 32. North America Molecular Diagnostics Cancer Market Size by Country (2017-2022) & (US$ Million) Table 33. North America Molecular Diagnostics Cancer Market Size by Country (2023-2028) & (US$ Million) Table 34. Europe Molecular Diagnostics Cancer Market Size by Country (2017-2022) & (US$ Million) Table 35. Europe Molecular Diagnostics Cancer Market Size by Country (2023-2028) & (US$ Million) Table 36. Asia-Pacific Molecular Diagnostics Cancer Market Size by Region (2017-2022) & (US$ Million) Table 37. Asia-Pacific Molecular Diagnostics Cancer Market Size by Region (2023-2028) & (US$ Million) Table 38. Latin America Molecular Diagnostics Cancer Market Size by Country (2017-2022) & (US$ Million) Table 39. Latin America Molecular Diagnostics Cancer Market Size by Country (2023-2028) & (US$ Million) Table 40. Middle East & Africa Molecular Diagnostics Cancer Market Size by Country (2017-2022) & (US$ Million) Table 41. Middle East & Africa Molecular Diagnostics Cancer Market Size by Country (2023-2028) & (US$ Million) Table 42. Roche Company Detail Table 43. Roche Business Overview Table 44. Roche Molecular Diagnostics Cancer Product Table 45. Roche Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 46. Roche Recent Development Table 47. Danaher Company Detail Table 48. Danaher Business Overview Table 49. Danaher Molecular Diagnostics Cancer Product Table 50. Danaher Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 51. Danaher Recent Development Table 52. Siemens Company Detail Table 53. Siemens Business Overview Table 54. Siemens Molecular Diagnostics Cancer Product Table 55. Siemens Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 56. Siemens Recent Development Table 57. Abbott Laboratories Company Detail Table 58. Abbott Laboratories Business Overview Table 59. Abbott Laboratories Molecular Diagnostics Cancer Product Table 60. Abbott Laboratories Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 61. Abbott Laboratories Recent Development Table 62. ICON Plc Company Detail Table 63. ICON Plc Business Overview Table 64. ICON Plc Molecular Diagnostics Cancer Product Table 65. ICON Plc Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 66. ICON Plc Recent Development Table 67. AstraZeneca Company Detail Table 68. AstraZeneca Business Overview Table 69. AstraZeneca Molecular Diagnostics Cancer Product Table 70. AstraZeneca Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 71. AstraZeneca Recent Development Table 72. MDxHealth Company Detail Table 73. MDxHealth Business Overview Table 74. MDxHealth Molecular Diagnostics Cancer Product Table 75. MDxHealth Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 76. MDxHealth Recent Development Table 77. Invitae Company Detail Table 78. Invitae Business Overview Table 79. Invitae Molecular Diagnostics Cancer Product Table 80. Invitae Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 81. Invitae Recent Development Table 82. PlexBio Company Detail Table 83. PlexBio Business Overview Table 84. PlexBio Molecular Diagnostics Cancer Product Table 85. PlexBio Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 86. PlexBio Recent Development Table 87. Thermo Fisher Scientific Company Detail Table 88. Thermo Fisher Scientific Business Overview Table 89. Thermo Fisher Scientific Molecular Diagnostics Cancer Product Table 90. Thermo Fisher Scientific Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 91. Thermo Fisher Scientific Recent Development Table 92. Guardant Health Company Detail Table 93. Guardant Health Business Overview Table 94. Guardant Health Molecular Diagnostics CancerProduct Table 95. Guardant Health Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 96. Guardant Health Recent Development Table 97. Biocartis Company Detail Table 98. Biocartis Business Overview Table 99. Biocartis Molecular Diagnostics CancerProduct Table 100. Biocartis Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 101. Biocartis Recent Development Table 102. Bio-Techne Company Detail Table 103. Bio-Techne Business Overview Table 104. Bio-Techne Molecular Diagnostics CancerProduct Table 105. Bio-Techne Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 106. Bio-Techne Recent Development Table 107. Merck Company Detail Table 108. Merck Business Overview Table 109. Merck Molecular Diagnostics CancerProduct Table 110. Merck Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 111. Merck Recent Development Table 112. Foundation Medicine Company Detail Table 113. Foundation Medicine Business Overview Table 114. Foundation Medicine Molecular Diagnostics CancerProduct Table 115. Foundation Medicine Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 116. Foundation Medicine Recent Development Table 117. 10X Genomics Company Detail Table 118. 10X Genomics Business Overview Table 119. 10X Genomics Molecular Diagnostics CancerProduct Table 120. 10X Genomics Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 121. 10X Genomics Recent Development Table 122. Biodesix Company Detail Table 123. Biodesix Business Overview Table 124. Biodesix Molecular Diagnostics CancerProduct Table 125. Biodesix Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 126. Biodesix Recent Development Table 127. CytoTrack Company Detail Table 128. CytoTrack Business Overview Table 129. CytoTrack Molecular Diagnostics CancerProduct Table 130. CytoTrack Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 131. CytoTrack Recent Development Table 132. GenomOncology Company Detail Table 133. GenomOncology Business Overview Table 134. GenomOncology Molecular Diagnostics CancerProduct Table 135. GenomOncology Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 136. GenomOncology Recent Development Table 137. Luminex Company Detail Table 138. Luminex Business Overview Table 139. Luminex Molecular Diagnostics CancerProduct Table 140. Luminex Revenue in Molecular Diagnostics Cancer Business (2017-2022) & (US$ Million) Table 141. Luminex Recent Development Table 142. Research Programs/Design for This Report Table 143. Key Data Information from Secondary Sources Table 144. Key Data Information from Primary Sources List of Figures Figure 1. Global Molecular Diagnostics Cancer Market Share by Type: 2021 VS 2028 Figure 2. Pharmacogenomic Diagnosis Features Figure 3. Liquid Biopsy Features Figure 4. Other Features Figure 5. Global Molecular Diagnostics Cancer Market Share by Application in 2021 & 2028 Figure 6. Respiratory Cancer Case Studies Figure 7. Cancer of Digestive System Case Studies Figure 8. Cancer of Urinary System Case Studies Figure 9. Cancer of Circulatory System Case Studies Figure 10. Motor System Cancer Case Studies Figure 11. Reproductive System Cancer Case Studies Figure 12. Other Case Studies Figure 13. Molecular Diagnostics Cancer Report Years Considered Figure 14. Global Molecular Diagnostics Cancer Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 15. Global Molecular Diagnostics Cancer Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 16. Global Molecular Diagnostics Cancer Market Share by Region: 2021 VS 2028 Figure 17. Global Molecular Diagnostics Cancer Market Share by Players in 2021 Figure 18. Global Top Molecular Diagnostics Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Diagnostics Cancer as of 2021) Figure 19. The Top 10 and 5 Players Market Share by Molecular Diagnostics Cancer Revenue in 2021 Figure 20. North America Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. North America Molecular Diagnostics Cancer Market Share by Country (2017-2028) Figure 22. United States Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Canada Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Europe Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. Europe Molecular Diagnostics Cancer Market Share by Country (2017-2028) Figure 26. Germany Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. France Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. U.K. Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Italy Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Russia Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Nordic Countries Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Asia-Pacific Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Asia-Pacific Molecular Diagnostics Cancer Market Share by Region (2017-2028) Figure 34. China Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Japan Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. South Korea Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Southeast Asia Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. India Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Australia Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Latin America Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Latin America Molecular Diagnostics Cancer Market Share by Country (2017-2028) Figure 42. Mexico Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Brazil Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Middle East & Africa Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Middle East & Africa Molecular Diagnostics Cancer Market Share by Country (2017-2028) Figure 46. Turkey Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. Saudi Arabia Molecular Diagnostics Cancer Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Roche Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 49. Danaher Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 50. Siemens Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 51. Abbott Laboratories Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 52. ICON Plc Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 53. AstraZeneca Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 54. MDxHealth Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 55. Invitae Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 56. PlexBio Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 57. Thermo Fisher Scientific Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 58. Guardant Health Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 59. Biocartis Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 60. Bio-Techne Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 61. Merck Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 62. Foundation Medicine Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 63. 10X Genomics Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 64. Biodesix Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 65. CytoTrack Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 66. GenomOncology Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 67. Luminex Revenue Growth Rate in Molecular Diagnostics Cancer Business (2017-2022) Figure 68. Bottom-up and Top-down Approaches for This Report Figure 69. Data Triangulation Figure 70. Key Executives Interviewed
Roche Danaher Siemens Abbott Laboratories ICON Plc AstraZeneca MDxHealth Invitae PlexBio Thermo Fisher Scientific Guardant Health Biocartis Bio-Techne Merck Foundation Medicine 10X Genomics Biodesix CytoTrack GenomOncology Luminex
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More